The Barostim Neo (CVRx) implantable pulse-generator system has gained US Food and Drug Administration (FDA) approval for reduced-ejection-fraction heart failure (HF) deemed unsuitable for other device therapies, the agency announced today.

Neuromodulation therapy using the Barostim, which resembles a standard pacemaker with a lead system but stimulates carotid baroreceptors, led to functional gains and improved quality-of-lifemeasures in the recent randomized BeAT-HF trial.

The pulse generator is typically implanted subcutaneously below the left or right collarbone with the lead positioned at the adjacent carotid sinus.

The approved FDA indication includes adults with medically refractory advanced HF and an ejection fraction ≤ 35%who aren't good candidates for other device therapies, especially cardiac resynchronization therapy.

Such patients, who have few other remaining treatment options short of ventricular assist devices or transplantation, make up perhaps half of patients with heart failure.

The treatment modality, called baroreflex activation therapy, is thought to counter neurohormonal effects of HF and ventricular remodeling by inhibiting sympathetic activity and enhancing parasympathetic activity, as previously described by theheart.org | Medscape Cardiology.

"As part of the approval of this device, the FDA is requiring the manufacturer to conduct a post-approval study investigating the potential of the therapy to prolong life and reduce the need for patient hospitalization," the agency said.

CPIPS2019

4th China Pharma IP Summit 2019 (CPIPS2019) organized by Shanghai YIP Events, Supported by Pharma IP Right Research Committee of Chinese Pharmaceutical Association, which will be held on 23rd-25th , Oct at Primus Hotel Shanghai Hongqiao China this year. which presents an unrivalled gathering of in-house patent counsel from established and fledgling pharmaceutical and biotechnology companies coming together to listen to updates on patent prosecution and enforceability from global jurisdictions,
The conference provides delegates with an invaluable opportunity to gain insight into the sector issues of critical current importance; listen to best-in-class case studies; keep abreast of the likely forward impact of key judgements and political jolts; and network with global patent peers.
As a dedicated event to pharmaceutical intellectual property, In the past three years we gathered more than 1000 attendees from relevant government departments, industry associations, global and china local pharma/biotech companies, law firms, IP agencies, IP solution providers and so on. Our topics covered the IP protection in all over the world, include mainly China, Europe, US, Japan, South Korea, India and Emerging Markets. We hope CPIPS could be a good networking and sharing platform for Industry peers, For more information please refer to below and attached agenda or visit conference website: www.pharmaip.cn